Sandoz announces winners of inaugural Healthcare Access Challenge #SandozHACk

NovartisSandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare Access Challenge (Sandoz HACk). The winners, chosen by a panel of judges at the Wired Health 2017 event in London, identified innovative approaches to address challenges in Ghana, the Maldives and the Philippines. The winning ideas all proposed novel ways to use mobile technologies to connect patients with caregivers and essential medicines, addressing access issues specific to their country but with the potential for solutions to be applied elsewhere.

The three winners were chosen from six finalists, out of a total of approximately 150 ideas submitted from 30 countries. All six presented their ideas to a panel of judges at Wired Health 2017, as part of the HACk "Live in London 2017" event.

Announcing the winners, Sandoz CEO and Division Head Richard Francis said: "Despite all the advances in modern medicine, universal access to healthcare is still arguably the single largest unmet medical need for people around the world."

He added: "We believe that the biggest changes often come from amazing, small ideas - and that the only thing standing between a good idea and a great idea is often just a bit of support at the right time. I see the future of medicine being driven by strong collaboration between healthcare companies and external partners. The Sandoz HACk is one way that we are trying to make this vision a reality."

Roberto Ascione, CEO of Healthware International and a member of the Sandoz HACk 2017 judging panel, said: "Increasing access to healthcare is one of the major challenges facing mankind today. No one person, or organization, can solve this on their own - that's why we all need to work together to find practical solutions to real problems. That's what Sandoz HACk is all about, and why I'm proud to be part of this great new access initiative."

To help support development of the six ideas prior to pitching them at Wired Health 2017, all six were given the chance to receive feedback from OpenIDEO, a global community of creative thinkers, technologists and others interested in helping social entrepreneurs. That feedback was also supplemented by contributions from functional experts within Sandoz.

The three winners, who will now receive EUR 20,000 each in funding to "bring their ideas to life" as well as ongoing support from Sandoz experts, are:

  • Blood Drive - in the Maldives, one out of 120 newborns has blood condition thalassemia. 85% of these children will not survive until age five unless they receive regular blood transfusions, but the scattered nature of the islands makes coordinating blood donations and banks very hard. This idea from Mohammed Shuraih and Yameen Rasheed aims to link islanders with a database of hospitals, who can send updates when they are running blood donation programs and use geolocation alerts to everyone nearby so that they can donate blood.
  • GoPharma - In Ghana, pharmacists don't generally work in rural areas and pharmacies are staffed by unskilled workers. This idea from Elvin Blankson and Priscilla Adu-Darko would connect pharmacists in towns with rural pharmacies, to make virtual appointments for advice on how to take medicines, contraindications etc.
  • Save-a-life - In the Philippines, basic first aid skills are mandated for inclusion in basic education, to help with the fact that ambulances find it hard to reach accidents quickly, given the distances involved and the challenging geography of the island nation. But most people don't yet have these skills. This app idea from Joel Alejandro and Andrea Relucio will help Filipinos who don't have the necessary training to perform CPR using auditory and visual guides, while also notifying emergency services.

For further information, please visit:
https://www.sandoz.com/making-access-happen

About the Sandoz HACk
Despite all the advances in modern medicine, universal access to healthcare is still arguably the single largest unmet medical need. At Sandoz we believe that the biggest changes often come from amazing, small ideas. Sometimes, the only difference between a good idea and a great idea is a little bit of support. That is where Sandoz HACk comes in – the Healthcare Access Challenge.

In September 2016 we called on young (18-35) creative thinkers to ‘re-imagine healthcare access’ and enter Sandoz HACk.

Using social media, we promoted the Sandoz HACk and asked for ideas that use mobile technology (M-Health) to connect people to better health.

Over the course of two months, we received around 150 ideas from over 30 countries. These were narrowed down to six finalists who were invited to come to London in March 2017 to present their ideas to a panel of judges at WIRED Health 2017. There, the six ideas were narrowed down to three winners from Ghana, the Maldives and the Philippines, each of whom will receive EUR 20,000 and ongoing mentorship to help make their idea a reality.

To ensure that the finalists were all equally well positioned for success, we gave them the opportunity to refine their ideas with feedback from OpenIDEO, a global community of creative thinkers, technologists and others interested in helping social entrepreneurs. That feedback was also supplemented by contributions from experts from Sandoz.

About Sandoz Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Amgen and Humana partner for improved health outco…

Two of the nation's leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to i...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]